- Home
- RUM vs CLDX Comparison
RUM vs CLDX Comparison
Compare RUM & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | CLDX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | RUM | CLDX |
|---|---|---|
| Price | $6.41 | $27.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $15.00 | ★ $43.80 |
| AVG Volume (30 Days) | ★ 3.4M | 775.5K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,782,153.00 | $2,599,000.00 |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $81.82 | $19.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.17 | N/A |
| 52 Week Low | $5.11 | $14.40 |
| 52 Week High | $17.40 | $30.50 |
Technical Indicators
Market Signals| Indicator | RUM | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 50.50 |
| Support Level | $6.97 | $27.51 |
| Resistance Level | $7.62 | $28.79 |
| Average True Range (ATR) | 0.40 | 1.30 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 6.60 | 28.48 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.